UPDATE: BMO Capital Downgrades Gilead Sciences (GILD) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500, Nasdaq set for higher open as investors weigh weaker oil, PPI data
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Birkenstock surges on revenue beat, higher full-year outlook
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Gilead Sciences (GILD) Has an 80% Chance of Trading Higher on this Catalyst - Morgan Stanley
February 24, 2022 9:04 AM ESTMorgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $69.00 price target on Gilead Sciences (NASDAQ: GILD) seeing an 80% chance that shares move higher when Trodelvy HR+/HER2- mBC data is reported in March. TROPiCS-02 is an ongoing Phase III, open-label, randomized, multicenter study of sacituzumab govitecan (Trodelvy) versus physicians choice (TPC) in patients with HR+/HER2- metastatic breast cancer (MBC) who have... More
Gilead Sciences (GILD) PT Raised to $54 at UBS
February 24, 2022 4:24 AM ESTUBS analyst Colin Bristow raised the price target on Gilead Sciences (NASDAQ: GILD) to $54.00 (from $52.00) while maintaining a Buy rating.... More
